Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Racura OncologyASX:RAC -6.10%25 EV-to-EBITDA is -34.66 as of Jul. 20, 2026. GuruFocus rates ASX:RAC with a GF Score™ of 25/100. Among 398 Biotechnology companies, Racura Oncology ranks worse than 251256.03% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Racura Oncology's enterprise value is A$396.69 Mil.
Racura Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-11.44 Mil. Therefore, Racura Oncology's EV-to-EBITDA for today is -34.66.
The historical rank and industry rank for Racura Oncology's EV-to-EBITDA or its related term are showing as below:
ASX:RAC'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -34.66 Med: 0 Max: 0
Current: -34.66
ASX:RAC's EV-to-EBITDA is ranked worse than 100% of 398
companies
in the Biotechnology industry
Industry Median: 12.205
vs ASX:RAC: -34.66
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Racura Oncology's PE Ratio (TTM) for today is calculated as:
Racura Oncology's share price for today is A$2.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Racura Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.054.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Racura Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RAC vs VRTX, REGN, ALNY: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Racura Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Racura Oncology EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Racura Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Racura Oncology's EV-to-EBITDA falls into.
Racura Oncology's current Enterprise Value is A$396.69 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Racura Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-11.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Racura Oncology (ASX:RAC) has a EV-to-EBITDA of -34.66 as of Jul. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Racura Oncology. According to the industry distribution chart, Racura Oncology ranks #999999 out of 398 companies in the Biotechnology industry.
Is Racura Oncology's EV-to-EBITDA too high?
Racura Oncology's current EV-to-EBITDA is -34.66. Based on the distribution chart, Racura Oncology ranks #999999 out of 398 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Racura Oncology has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #999999 out of 398 companies for EV-to-EBITDA. This places Racura Oncology in the lower half of its industry. The industry median EV-to-EBITDA is 12.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.21, based on 398 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Racura Oncology. For the Biotechnology industry, the median EV-to-EBITDA is 12.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Racura Oncology's current EV-to-EBITDA is -34.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current EV-to-EBITDA of -34.66. The current EV-to-EBITDA is -34.66. Racura Oncology's overall GF Score™ is 25/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current EV-to-EBITDA is -34.66 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
25GF Score
Get the complete analysis for ASX:RAC
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RAC has been successfully added to your 
